Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Suzanne Richter, MD, MSc, FRCPC,* J. Dean Ruether, MD; Lori Wood, MD, MSc; Christina Canil, MD, FRCPC; Patricia Moretto, MD; Peter Venner, MD; Joel Gingerich, MD, FRCPC; Urban Emmenegger, MD; Andrea Eisen, MD, FRCPC; Pawel Zalewski, MD, FRCPC; Anthony Joshua, MBBS, PhD, FRACP; Som Dave Mukherjee, MD, MSc, FRCPC; Daniel Heng, MD; Piotr Czyzakowski, MD, MSc, FRCPC; Denis Soulieres, MD; Norman Blais, MD, MSc; Ricardo Rendon, MD, FRCSC; Neil Fleshner, MD, FRCSC, MPH; Juanita M. Crook, MD, FRCPC; Srikala S. Sridhar, MD, MSc, FRCPC

*Clinical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON
†Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
‡Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
§Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©Department of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
©©Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON
†††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
†††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
††††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
†††††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
††††††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
†††††††††Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
‡‡‡‡‡‡‡‡‡Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
§§§§§§§§§Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
¶¶¶¶¶¶¶¶¶Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON
©©©©©©©©©Division of Medical Oncology, Sunnybrook Research Institute, Toronto, ON

Introduction

Penile cancer occurs in about 1 in 100 000 men annually in developed countries.1 In Canada, penile cancer is reported under “genito-urinary, other and unspecified” in the annual Cancer Statistics and accounts for about 200 new cases and 30 related deaths.2 Similarly, the American Cancer Society statistics for 2011 estimated 1360 new cases and 320 penile cancer-related deaths.3

Penile cancer most commonly affects men between the ages of 65 to 74 years, and presents with well or moderately differentiated disease. Although most cases are localized, about 25% of patients will have regional involvement and 4% will have distant disease at the time of diagnosis.4 The most powerful prognostic indicator in the absence of distant disease is nodal involvement. The 5-year survival rate for carcinoma in situ is over 90%, but drops to 60% with nodal involvement and to 20% for patients with metastatic disease.4,5

Due to the low incidence of this disease, management is often guided by case reports, small case series and local experience. No Canadian guidelines or consensus statements currently exist to guide the diagnosis and management of these patients. The European Association of Urology (EAU) has published guidelines on the management approach to penile cancer, but recent data published by Johnson and colleagues6 suggest that these recommendations have not been widely applied in North America.5,6

Our objective was to develop the first Canadian Consensus Statement on the management of penile cancer for Canadian oncologic specialists treating genitourinary cancers based on available evidence, existing guidelines and expert Canadian opinion to better address the needs of patients with penile cancer in Canada.

Methodology

In June 2011, a group of Canadian genitourinary medical oncologists attended the annual Canadian Genitourinary Medical Oncology (CAGMO) meeting to discuss the management of penile cancer. Key references, including the EUA guidelines and provincial guidelines (British Columbia and Alberta), were reviewed. The modified version of the Oxford Levels of Evidence and Recommendation Grading7 (Table 1) was used to grade the evidence and recommendations. Surgical approaches were reviewed but not graded.

A search of MEDLINE, Cochrane and EMBASE databases (Jan 1988-Feb 2012) was included to evaluate data; we also reviewed the recent guidelines from the EUA,5 National Comprehensive Network Cancer,8 and the International Consultation on Penile Cancer.4 Search terms included penile cancer or cancer of the penis or carcinoma of the penis or penile carcinoma with systemic therapy or chemotherapy as the topic of interest with an English language limit. Retrospective and prospective study designs which evaluated progression-free survival or overall survival benefit of systemic therapy in 10 or more individuals with squamous cell carcinoma of the penis were included. Opinion from Canadian experts in medical oncology, radiation oncology,
and uro-oncology was also incorporated into the consensus statement. The manuscript was evaluated using the AGREEII instrument. A planned update will occur in 5 years.

Penile cancer risk factors

The main risk factors for penile cancer with an odds ratio >10 include phimosis, chronic inflammatory conditions of the penis, treatment with psoralen and ultraviolet A phototherapy, a history of multiple sexual partners, and early age at first intercourse. History of condylomata is associated with a 6-fold increase in the risk of penile cancer. History of smoking is associated with a 3- to 4.5-fold increase in risk and is an independent risk factor regardless of sexual history.

Circumcision

Circumcision is a controversial issue that weighs the rights for individual choice and potential for disease prevention against the risk of complications and cost-effectiveness of a population-based program. Although several series and a meta-analysis support a reduction in both Human papilloma virus (HPV) and penile cancer prevalence with circumcision, routine neonatal circumcision has been delisted in every province across Canada due to an unfavourable benefit-to-harm ratio.

Human papilloma virus and vaccination

HPV prevalence in penile cancer is about 50%, with a presumed link to causality in a recent large systematic review. The serotypes commonly associated with other anogenital malignancies are also most frequent in men with penile cancer, including HPV16 (60%) and HPV18 (13%). In contrast, the incidence of HPV infection on the foreskin of unaffected men is 0 to 6%. The role for vaccination against HPV and associated conditions remains controversial. The quadrivalent vaccine HPV4 (Gardasil, Merck & Co.) is directed against HPV6, 11, 16, and 18. The bivalent HPV2 vaccine (Cervarix, GlaxoSmithKline) is directed against HPV16 and 18. Both vaccines are approved by Health Canada for use in females. The HPV4 vaccine is FDA-licensed for use in males to protect against genital warts and anal cancer. In 2010, Health Canada approved the HPV4 vaccine for males aged 9 to 26 years old. However to date, no province has implemented routine male vaccination.

The impact of vaccination on early penile cancer lesions was one of several endpoints in a recent clinical trial. In the phase III randomized, placebo-controlled trial of HPV4, no statistically significant effect against grade 1 to grade 3 penile intraepithelial neoplasia was demonstrated. The limitations of this trial include the narrow participant age-range and a current short follow-up period of 2.9 years.

HIV

Penile cancer is increased 8-fold in individuals affected by HIV. The reason for this observation is not fully elucidated and may be due to increased incidence of HPV infection.

Staging of the primary

Clinical staging of the primary

Penile carcinoma often presents with a visible or palpable lesion that may be accompanied by pain, bleeding or discharge. Often these lesions are hidden under a phimotic foreskin which can delay diagnosis. A high index of suspicion is required in the setting of a penile lesion or if there is a history of bleeding or discharge from a non-retractile foreskin.

Staging of the primary lesion includes physical examination with attention to morphologic appearance, location, and extent. Magnetic resonance imaging (MRI) of the penis with prostaglandin E1-induced erection is considered one of the most sensitive imaging modalities to determine the depth of corporal invasion. Ultrasound may also serve as an adjunct to physical examination for determining infiltration into the corpus cavernosum. Computed tomography (CT) imaging is not sufficient to determine the depth of tumour penetration locally, but it is useful to detect enlarged lymph nodes.

Pathological reporting of the primary

At presentation, excisional biopsy is favoured. However if a diagnostic biopsy is performed, this must often be preceded by either a dorsal slit of the foreskin or circumcision to expose the lesion.
Penile cancer is predominantly of squamous cell histology (95%) with several subtypes, including verrucous carcinoma, basaloid carcinoma, warty carcinoma (verruciform), and neuroendocrine carcinoma. Malignant melanoma and basal cell carcinoma account for the remainder of penile cancer cases. Among the different histologies, sarcomatoid variants have the worst prognosis, with an 89% risk of lymph node invasion. The main components in a pathology report should include: anatomic site, tumour size, histologic type, grade, growth pattern, invasive front, depth of invasion, tumour thickness, resection margins, lymphovascular invasion, and perineural invasion. These components play a critical role in determining both prognosis and treatment.

Penile cancer is staged according to the American Joint Committee on Cancer (AJCC) Tumour, Node, Metastases (TNM) guidelines (Table 2). Important changes in the recent 2010 publication of AJCC TNM guidelines include the distinction between T1a and T1b lesions. T1a lesions are defined by grade 1 or 2 histology and by the absence of lymphovascular invasion. T1b lesions are defined by grade 3 or 4 histology or the presence of lymphovascular invasion. The significance of differentiating these lower risk lesions from their higher risk counterparts is to better identify those patients who may benefit from early lymph node dissection in the setting of clinically negative inguinal lymph nodes. Other important changes include the upgrading of prostatic invasion to category T4 and any lymph node involvement to at least a stage III (Box 1).

### Staging the lymph nodes

**Clinical uninvolved lymph nodes**

In penile cancer, lymph node involvement (in the absence of distant disease) is the most powerful prognostic indicator. Regional spread occurs from the inguinal nodes to the pelvic lymph nodes. Physical examination of the inguinal nodes therefore must be performed. At the time of diagnosis, about 50% of patients will have palpable nodes. In half of these men, the adenopathy is related to metastatic disease. The evidence for lymph node management was recently reviewed and showed that clinically abnormal lymph nodes may require a different management strategy than those that are clinically negative.

The lymph nodes are clinically staged on the basis of palpable inguinal lymphadenopathy. An assessment of the number of nodes involved, size, laterality, and mobility should be performed. Ultrasound has some value identifying metastatic lymph nodes based on architectural change and can increase the diagnostic yield for metastases greater than 2 mm. In some cases, the ability to palpate inguinal

---

**Table 2. American Joint Committee on Cancer for staging of penile cancer**

<table>
<thead>
<tr>
<th>Primary tumour</th>
<th>Clinical stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX Primary tumour cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T0 No evidence of primary tumour</td>
<td></td>
</tr>
<tr>
<td>Tis Carcinoma in situ</td>
<td></td>
</tr>
<tr>
<td>Ta Noninvasive verrucous carcinoma</td>
<td></td>
</tr>
<tr>
<td>T1a Tumour invades subepithelial connective tissue without lymphovascular invasion and is not poorly differentiated (grade 3-4)</td>
<td></td>
</tr>
<tr>
<td>T1b Tumour invades subepithelial connective tissue with lymphovascular invasion or is poorly differentiated</td>
<td></td>
</tr>
<tr>
<td>T2 Tumour invades corpus spongiosum or cavernosum</td>
<td></td>
</tr>
<tr>
<td>T3 Tumour invades urethra</td>
<td></td>
</tr>
<tr>
<td>T4 Tumour invades other adjacent structures</td>
<td></td>
</tr>
</tbody>
</table>

**Box 1. Staging of the penile primary**

**Recommendations**

1. Clinical staging of the primary requires physical examination of the penis to determine extent of involvement. Imaging may be considered helpful in further delineating involvement. When imaging is considered, either MRI or ultrasound should be used (Grade C).
2. Pathologic reporting should adhere to the most recent AJCC guidelines.
lymph nodes is hampered by body mass index and prior treatment. In a thin patient, normal inguinal lymph nodes may be readily palpable. In obese men, the clinical exam may be supplemented by imaging. The European Association of Urology (EAU) reports that CT imaging is used most commonly for imaging the inguinal lymph nodes despite a low sensitivity of 36%. A CT is valuable in identifying high-risk patients based on the presence of central node necrosis and irregular borders. Lymphotropic nanoparticle-enhanced MRI demonstrated high sensitivity (100%) and specificity (97%), with a positive predictive value of 81.2% for micrometastatic disease. This encouraging data, however, were generated in a small sample size and remain dependent on institutional expertise. Similarly, a positron emission tomography (PET) scan was shown to have a positive predictive value of 94% and a negative predictive value of 96%. These data were generated in a 2012 prospective trial evaluating 35 patients; this trial suggested the possible utility of penile cancer staging, but the topic warrants further prospective evaluation in larger studies. Currently, MRI is a reasonable choice to supplement physical exam in individuals in whom access to the inguinal regions is difficult; it also allows for concurrent evaluation of the primary.

**Box 2. Staging of the lymph nodes**

**Recommendations**

- Clinical staging of the inguinal lymph nodes requires physical examination. Ultrasound with fine needle aspiration can increase the diagnostic yield in individuals with palpable nodes (Grade C).
- Physical examination in individuals with clinically uninvolved nodes can be supplemented by MRI, CT or PET in individuals where clinical assessment alone is difficult (Grade C).
- Abdominopelvic imaging in individuals with clinically involved nodes can assess the presence of pelvic and retroperitoneal lymph nodes (Grade C).

**Surgical management of the penile primary tumour**

**Stage Tis, Ta**

Tis and Ta are in situ and noninvasive lesions, respectively. Treatment options include local excision with or without circumcision, carbon dioxide or neodymium:yttrium-aluminum-garnet (Nd:YAG) laser therapy, and photodynamic therapy. Verrucous carcinoma can be treated with Mohs micrographic surgery; recurrent superficial lesions may be treated with 5-fluorouracil or 5% imiquimod cream as topical therapy. There are no clinical trials or comparative studies to indicate which approach is superior. The key concept is that superficial disease should be managed by penile-sparing approaches, lessening the negative impact of treatment on quality of life. Treatment decisions are guided by tumour features, local expertise, and patient preference.

**Stage T1**

Category T1a lesions limited to the foreskin are superficial and can be managed by the same conservative approaches used in Tis and Ta disease. Category T1b lesions are now a distinct group from their T1a counterparts in the most recent AJCC staging system to differentiate lesions that, on the basis of high histologic grade (Grade 3-4) or lymphovascular invasion, are more likely to be associated with inguinal lymph node involvement. Since these T1b lesions are also upstaged to stage 2, more aggressive approaches are indicated. Surgical options include partial penectomy or glansectomy. For smaller lesions, neoadjuvant chemotherapy (including vinblastine, bleomycin, and methotrexate) followed by CO2 laser excision has been reported, but is not commonly used in Canada. Radiotherapy for lesions under 4 cm can be used. Further discussion is found in the radiation section. Careful follow-up for local recurrences is required.
Management of carcinoma of the penis

Stage T2

In individuals with T2 disease limited to the glans, surgical options include total glansectomy with or without resurfacing of the corporeal heads. It is appropriate to selectively use partial glansectomy in patients with no urethral invasion and patients amenable to close monitoring for local recurrence.50 Partial penectomy should be considered where more conservative reconstructive surgery is not appropriate or for large...
tumours involving more than the distal corpora. Although the traditional 2-cm proximal margin allows for disease control while preserving voiding function, more recent data suggest that a 5 to 10-mm margin may be sufficient. Radiation, either as brachytherapy or external beam, is an alternative to surgical approaches and, similar to T1 lesions, is best used for lesion under 4 cm (see section Radiation).

Within the T2 category, cavernosal involvement may portend a worse prognosis than spongiosum involvement alone. However, to date, this distinction is not reflected in the AJCC staging guidelines.

**Stage T3 and T4**

Total penectomy with perineal urethrostomy is standard for T3 tumours and is recommended by the EAU. In T4 disease, most patients will have fixed inguinal and involved pelvic lymph nodes with a poor prognosis. Neoadjuvant chemotherapy (discussed specifically in the Chemotherapy section) or chemoradiotherapy (discussed in the Radiation section) should be considered. In the absence of neoadjuvant therapy, adjuvant chemotherapy or consolidation with radiation therapy is suggested by the EAU and is discussed further in the respective sections (Box 3).

**Box 3. Surgical management of the primary tumour**

**Recommendations**

Penile preserving approaches should be considered for Tis-Ta and T1 disease in the absence of grade 3 or more histology to balance local recurrence rates, maintenance of function and quality of life. (Grade B).

Total penectomy with perineal urethrostomy is recommended for T3 lesions (Grade B).

Neoadjuvant chemotherapy or chemo-radiotherapy is advised prior to surgery for T4 lesions (Grade C).

**Surgical management of the lymph nodes**

**Clinically involved lymph nodes**

Individuals with clinically suspicious lymph nodes should undergo fine needle aspiration/cytology. Those individuals with histologically confirmed lymphadenopathy under 4 cm should undergo ipsilateral lymph node dissection and a contralateral staging superficial inguinal node dissection. Further surgery can be based on the findings from this primary surgery (see Pelvic lymph nodes section). Individuals with multiple or bilaterally clinically involved nodes are predicted to have N2 disease and they may benefit from neoadjuvant chemotherapy. In patients with multiple, bulky or involved pelvic lymph nodes, multimodality approaches (including primary chemotherapy followed by surgery and node dissection) are preferred on the basis of a small number of retrospective studies (see Chemotherapy section) (Fig. 1).

**Clinically uninvolved lymph nodes**

In cases where lymph nodes are not clinically palpable or visibly enlarged radiographically, metastatic involvement will be present in 10% to 20% of lymph node dissections. Currently, the extent and timing of inguinal lymphadenectomy with or without sentinel biopsy remain controversial. We propose an algorithm for the management of the lymph nodes based on clinical involvement (Fig. 1). At centres with the appropriate expertise, dynamic sentinel lymph node biopsy (which involves the injection of technetium-99m around the primary tumour), preoperative lymphoscintigraphy, and sentinel lymph node (SLN) identification using blue dye and a gamma ray detection probe to achieve physiologic rather than anatomic SLN identification may be considered. DSNB compares favourably to bilateral inguinal lymph node dissection by detecting similar rates of nodal metastases, but with less postoperative morbidity. If the sentinel lymph node biopsy is positive, ipsilateral therapeutic, radical inguinal lymph node dissection should be performed.

Early inguinal lymph node dissection in men with clinically negative nodes, but at high risk for nodal involvement, significantly improves cancer-specific survival and can be curative in 20% to 60% of histologically node-positive patients. However, even in node-negative men, inguinal lymph node dissection does not guarantee survival, with a 5-year recurrence-free rate of 75% to 95%. While inguinal lymph node involvement is one of the strongest predictors in penile cancer, inguinal lymph node dissection must be weighed against the resulting morbidity, including infection, wound necrosis, and chronic leg edema. Therefore, the timing of inguinal lymph node dissection is an important consideration. Early inguinal lymph node dissection occurs within 6 weeks of primary tumour treatment in the absence of palpable lymph nodes. Delayed treatment is defined as dissection at the time of palpable node identification during follow-up. The potential benefits of delaying inguinal lymph node dissection were historically to allow a 6-week course of antibiotic treatment, a regression of any inflammatory nodes, a decrease in the risk of wound infection, and possible avoidance of unnecessary surgery and its associated morbidity. However, recent evidence demonstrates improved survival outcomes without increased morbidity with early inguinal lymph node dissection when compared to delayed dissection. The need to balance the benefits of nodal dissection with the known morbidity has led to the development of models designed to predict the likelihood of nodal metas-
tases. Individuals predicted as high risk of lymph node involvement can undergo early inguinal lymph node dissection, while those predicted to be at lower risk can opt for ongoing surveillance. Risk stratification can be based on the primary tumour histology. The presence of T2G2 or T2-3 G3 disease predicts lymph node involvement in up to 81% of cases. More recently, disease ≥T1G3 has been considered high-risk disease. Predictions based on histologic criteria alone, however, are not highly reliable. Efforts to improve accuracy have led to the development of several nomograms. Three important points should be noted: (1) these tools remained largely unvalidated in prospective studies; (2) not all features can be determined for individuals undergoing penile conserving treatment; and (3) sensitivity, specificity, and false-negative rate are variable and are inferior to recent reports of high sensitivity (94%) using dynamic sentinel node biopsy. Therefore when available, DSNB is preferred for risk stratification over nomograms. In line with these caveats, both the EAU and the National Comprehensive Cancer Network (NCCN) recommend tailoring a lymph node dissection based on clinical stage. Therefore, patients who are deemed compliant with no palpable lymphadenopathy and pTis, PTa and pT1G1 disease can undergo surveillance, while undergoing either modified bilateral lymphadenectomy or sentinel node dissection in the absence of palpable lymph nodes. Radical lymphadenectomy can be reserved for those patients with histologically proven inguinal lymph node involvement.

Pelvic lymph nodes

Involvement of the pelvic lymph nodes is not expected in the absence of inguinal lymph node involvement. If cancer is found in the inguinal nodes, ipsilateral pelvic (iliac) lymph node dissection should be considered in highly selected patients because about 30% of these nodes will harbor metastases. The likelihood of positive pelvic nodes is 23% for 2 positive inguinal nodes and 56% for either 3 involved nodes or extracapsular extension. Involvement of the most proximal (Cloquet’s) node has a sensitivity of 30% and specificity of 94% for pelvic lymph node metastases. Increased risk of pelvic node involvement is also associated with the lymph node ratio (number of positive nodes/total number removed) and increased p53 expression. It has been suggested that patients with a single involved inguinal lymph node, an uninvolved most proximal (Cloquet’s) node, no evidence of extranodal extension, and no grade 3 tumour in an inguinal node do not benefit from pelvic lymph node dissection (PLND). For individuals with suspected pelvic node involvement, histologic confirmation should be sought because the presence of pelvic node metastases would indicate consideration of neoadjuvant therapy. PLND should occur by an open as opposed to a laparoscopic approach.

Advances in surgical techniques

The goals of treatment are to maximize potential for cure, while also to minimize morbidity using penile preservation where possible. Appropriately selecting patients for management of nodal disease (in the hopes of limiting the potential morbidity complications of lymph node dissection are also treatment goals. Treatment of penile cancer has a significant effect on psychosocial and sexual functioning – a patient’s quality of life.

Modified inguinal lymph node dissection has been proposed to minimize morbidity, while maintaining therapeutic benefit. A recent analysis assessed the impact of modified inguinal lymph node dissection on morbidity and survival. The authors concluded that the extent of lymph node dissection should be adapted to clinical stage, as this corresponds to metastatic spread. Low-risk patients with pTis, pTa, or pT1G1 disease, without palpable nodes and with good compliance, can undergo surveillance (Fig. 1). All other patients without palpable lymph nodes, including intermediate risk pT1G2 disease, should undergo modified bilateral lymphadenectomy in the absence of DSNB or histologic confirmation. The authors further recommended PLND in patients with more than 2 metastatic inguinal lymph nodes, although the therapeutic benefit of this approach is undemonstrated and limb morbidity increases significantly. In case of fixed inguinal lymph nodes or nodes 4 cm or greater, neoadjuvant chemotherapy or chemoradiotherapy is recommended, followed by node dissection.

Another alternative to radical inguinal lymph node dissection is video endoscopic inguinal lymphadenectomy, which can result in lower complication rates and shorter hospitalization than standard inguinal lymph node dissection. However, the data are not mature and longer follow-up is required to determine the false-negative and survival rates. The technique is not considered standard of care at this time (Box 4).

Radiation treatment of the primary tumour

The recent EAU and NCCN guidelines support radiation therapy as a possible organ-preserving approach. It is most
commonly used for T1 or T2 disease measuring <4 cm as either external beam radiation or brachytherapy. Penile preservation after primary external beam radiotherapy was evaluated by McLean and colleagues. Patients stage T1-2 N0, received external beam radiation (35-60 Gy) to the primary tumour with or without radiation to the regional lymph nodes, leaving surgery for salvage upon relapse. Local control rate was 62% and the penile preservation rate was 66%. Patients who underwent salvage penectomy remained disease-free. More recent data demonstrate an 88% 5-year survival rate with external beam radiotherapy, with inferior local control compared to penectomy. Superior local control is achieved using brachytherapy, with 5-year penile preservation rates of 70% to 88% and 10-year penile preservation rates of 67% to 72% (Level of evidence 2b). Cause-specific survival is similar to primary surgical approaches as salvage surgery is highly effective. Squamous carcinoma of the penis is a highly radiosensitive tumour, but radical doses in this site can result in complications including soft tissue necrosis (12%) or meatal stenosis (9%). Soft tissue necrosis often responds to conservative measures, including hyperbaric oxygen treatment, and only rarely requires amputation. Meatal stenosis can be prevented and/or effectively managed using a meatal dilator. Both these complications increase with increasing stage and tumour volume (Box 5).

**Box 5. Radiation therapy in the management of the primary tumour**

**Recommendations**

Brachytherapy or external beam radiation alone can be used as a penile preserving approach for tumours <4 cm that are not extending beyond the glans (Grade B)

**Radiation treatment of the lymph nodes**

Prophylactic nodal radiation is not recommended for clinical N0 patients. It is not associated with a decreased risk of subsequent nodal metastasis, and its use in this setting may cause unnecessary radiation-associated morbidity and fibrotic changes that can complicate follow-up.

Radiotherapy may be used in the neoadjuvant setting to downsize unresectable lymph nodes. An increased risk of nodal relapse >15% is an indication for adjuvant radiotherapy for some tumour sites. For tumours with natural histories and lymph drainage similar to that of penile cancer (vulvar and anal cancer), lymph node irradiation is usually indicated, either as a neoadjuvant approach to surgery or as part of combined modality. Series evaluating the benefit of nodal radiation therapy are limited. One of the largest series evaluated 120 patients with nodal metastases. Of the 33 patients who received neoadjuvant nodal radiation, only few had evidence of extranodal extension (8%) or disease recurrence (3%). These data compare favourably to historic data, suggesting 33% extranodal extension and 19% nodal recurrence. These data are used to support the use of radiation therapy to improve local control for lymph nodes of 4 cm or more without skin fixation. Similarly, combined modality treatment is the standard of care in squamous anal cancer through 4 key trials. An extrapolation from these studies supports the use of combined modality in penile cancer, particularly for individuals with inoperable inguinal lymph nodes. This approach is already in widespread use in tertiary referral centres while we await the results from a contemporary large cooperative international trial assessing neoadjuvant multimodality therapy for bulky or inoperable inguinal nodes. In the interim, by extrapolation of data from other squamous cell cancers, we agree with NCCN’s recommendation of cisplatin or mitomycin, either alone or in combination with 5-FU, for concurrent use with radiotherapy.

In tumours of the penis, where locoregional control highly predicts prognosis, adjuvant inguinopelvic radiation may reduce the risk of recurrence in high-risk patients. If the status of the deep pelvic nodes is unknown, radiation to the pelvis may be included. If pelvic nodes are known to be histologically negative, radiotherapy can be limited to the inguinal region with a boost if necessary for known extracapsular disease (Box 6).

**Box 6. Radiation therapy in the management of the lymph nodes**

**Recommendations**

Prophylactic RT is not recommended in N0 disease (Grade C). Adjuvant (or neoadjuvant) RT of 45-70 Gy in cases of extensive metastases or extranodal spread improves locoregional control (Grade C). We are not yet able to clearly delineate which individuals will benefit from neoadjuvant vs. adjuvant treatment. Consider concurrent treatment with radiation and chemotherapy (such as 5-FU) by extrapolation of squamous cell cancer studies in other tumour sites can be considered (Grade C).

**Using radiation in palliation**

Radiation therapy has the potential to reduce tumour size and provide local decompression. In patients with pelvic lymph node recurrence, radiation may palliate pain and lower extremity lymphedema. Published studies on this indication are rare. In cases of inguinal relapse, radiation therapy may reduce the risk of ulceration and bleeding. Chronic ulcers following radiation therapy should be considered recurrence until proven otherwise. In summary, palliative external beam radiation therapy can be considered for locally advanced metastatic disease.
Management of carcinoma of the penis

Chemotherapy in the management of penile cancer

Neoadjuvant chemotherapy

Neoadjuvant chemotherapy is defined as the use of systemic therapy (chemotherapy) before definitive local therapy. Neoadjuvant therapy aims to downstage or reduce the size or extent of the cancer to facilitate local treatment. In addition, neoadjuvant chemotherapy may eliminate micrometastatic disease. For example, in breast cancer treatment, pathological complete response has been correlated with improved long-term outcomes.81

For patients with palpable lymph nodes and especially with large, immobile inguinal nodal metastases, recent studies have shown promising results for neoadjuvant chemotherapy followed by surgical node dissection. A small number of studies have been performed (Table 3). In a retrospective analysis, 12 out of 19 patients receiving neoadjuvant chemotherapy with different regimens (vincristine/bleomycin/methotrexate, cisplatinum/bleomycin/methotrexate, cisplatinum/5-FU or cisplatinum/irinotecan) responded, and 8 of these patients achieved long-term survival after subsequent resection of the inguinal lymph node metastases.57 Bermejo and colleagues reported a complete response in 4 out of 5 patients receiving neoadjuvant treatment with paclitaxel/cisplatinum/ifosfamide, 3 of whom had a histologically demonstrated complete response.82 Cisplatin-based combinations showed similar benefit to bleomycin containing regimen in penile cancer, while avoiding the observed significant bleomycin-related toxicity. With these available alternatives, bleomycin containing regimens are

Table 3. Clinical trials for neoadjuvant chemotherapy in squamous cell carcinoma of the penis

<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Regimen</th>
<th>n</th>
<th>Clinical stage N (%) surgery</th>
<th>RR %</th>
<th>PFS median</th>
<th>OS median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bermejo et al.52</td>
<td>Retrospective</td>
<td>BMP</td>
<td>10</td>
<td>N1-3,or M1</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bleomycin 10 mg/m² day 1-6</td>
<td>Methotrexate 200 mg day 1, 15, 21</td>
<td>Cisplatinum 20 mg/m² day 1-5</td>
<td>Every 4 weeks, 2-9 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PCA</td>
<td>10</td>
<td>N1-3,or M1</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paclitaxel 80-200 mg/m²</td>
<td>Carboplatin (AUC 6)</td>
<td>Every 3 weeks x 4 cycles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIP</td>
<td>10</td>
<td>N1-3,or M1</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paclitaxel 175 mg/m² day 1-5</td>
<td>Ifosfamide 1.2 g/m² day 1-3</td>
<td>Cisplatin 20 mg/m² day 1-3</td>
<td>Every 21 days, 4-5 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bleomycin</td>
<td>Bleomycin 15 mg day 1 and 3</td>
<td>Weekly x 12 max</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMP</td>
<td>10</td>
<td>N1-3,or M1</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bleomycin 15 mg/m² day 1 and 2</td>
<td>Methotrexate 30-50 mg day 3</td>
<td>Cisplatinum 20 mg/m² day 2-5</td>
<td>Every 3 weeks, max 5 cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BVM</td>
<td>10</td>
<td>N1-3,or M1</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vincristine 1 mg/m²</td>
<td>Bleomycin 15 mg/m²</td>
<td>Methotrexate 30 mg/m²</td>
<td>Weekly x 12 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CF</td>
<td>20</td>
<td>T4 or N3</td>
<td>9 (45)</td>
<td>12 (60)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cisplatinum 100 mg/m2</td>
<td>5-fluorouracil 1000 mg/m2 day 1-5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CI</td>
<td>20</td>
<td>T4 or N3</td>
<td>9 (45)</td>
<td>12 (60)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cisplatinum 80 mg/m² on day 1</td>
<td>Irinotecan 60 mg/m² on day 1, day 8</td>
<td>every 2 weeks, max 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ITP</td>
<td>30</td>
<td>Any T, N2-3</td>
<td>22 (73.3)</td>
<td>15 (50)</td>
<td>8.1 months</td>
</tr>
<tr>
<td></td>
<td>Phase II</td>
<td>Paclitaxel 175 mg/m² day 1</td>
<td>Ifosfamide 1200 mg/m² day 1-3</td>
<td>Cisplatinum 25 mg/m² day 1-3</td>
<td>Every 3 weeks x 4 cycles</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RR: response rate; PFS: progression-free survival; OS: overall survival.
The first prospective series of neoadjuvant chemotherapy was recently published. Similarly, promising data with the same neoadjuvant regimen were reported by Pagliaro and colleagues, with 15 of 30 patients achieving a response and 9 patients long-term survival. The treatment was well-tolerated; the most common significant toxicity was grade 3 infection. Pizzocaro and colleagues used a neoadjuvant regimen of paclitaxel/cisplatinum and 5-FU and reported a response in all 3 patients treated.

For patients with penile carcinoma and fixed inguinal lymph node metastases or mobile nodes of 4 cm or greater, neoadjuvant chemotherapy followed by lymph node dissection should be given to patients whose disease responds to treatment. There is also likely to be a benefit in patients with N2 disease, but data are lacking. Again, while the principle seems to be established, it is unclear which, if any, of the possible chemotherapy regimens is most suitable, how many cycles should be given, and what the time interval should be between chemotherapy and surgery. Data about the relative rate of complications in patients undergoing inguinal lymphadenectomy with or without neoadjuvant chemotherapy are also lacking (Box 7).

### Box 7. Neoadjuvant chemotherapy

**Recommendations**

Neoadjuvant chemotherapy can be considered for inguinal lymph nodes measuring 4 cm or more (fixed or mobile) (Grade C).

Neoadjuvant regimen should contain cisplatinum. Bleomycin-containing regimen should not be used. Neoadjuvant regimen have not been evaluated in randomized studies to allow a strong recommendation of one regimen over another. (Grade C). An acceptable example is four cycles of paclitaxel 175 mg/m² on day 1, ifosfamide 1200 mg/m² on d1 to 3 and cisplatinum 25 mg/m² on day 1 to 3.

Neoadjuvant regimen or chemoradiation should be considered first line treatment for N2-3 disease. Surgery should be offered to those with evidence of response to neoadjuvant chemotherapy (Grade C).

Adjuvant chemotherapy

Adjuvant chemotherapy is defined as the use of systemic therapy after definitive local therapy to eradicate micrometastases and reduce the risk of recurrence. Adjuvant chemotherapy in completely resected penile cancer with adverse features has not been rigorously tested (Table 4). Based on a contemporary series of patients treated with surgery alone, the 2-year disease-free survival rate in patients with bilateral inguinal metastases is 53.1%, while 3-year survival rates are 21.2%. Thus, surgery alone is often inadequate to prevent disease recurrence. The EAU currently recommends, however, that adjuvant chemotherapy should be offered to patients with N2 (palpable, mobile and multiple lymph nodes, uni- or bilateral) disease, while the NCCN recommends adjuvant chemotherapy for lymph node size 4 cm or more. This is on the basis of a retrospective study by Pizzocaro and colleagues. In this small study, 12 patients with surgically resected inguinal lymph node metastases who had adjuvant vincristine, methotrexate, bleomycin chemotherapy were compared with historic controls who did not receive chemotherapy. The 5-year survival rate was 82% with adjuvant chemotherapy compared with 37% in the historic control group. In addition, none of the stage N1 patients (palpable, mobile unilateral lymph node metastases) who received chemotherapy developed progressive disease. Pizzocaro and colleagues also evaluated patients treated with either 12 weeks of vinblastine-bleomycin-methotrexate (VBM) or cisplatin-5-FU in the adjuvant setting. Adjuvant VBM was associated with an 84% disease-free survival compared to 39% in historic controls. However, treatment with bleomycin in these studies was associated with significant toxicity.

### Table 4. Clinical trials for adjuvant chemotherapy in squamous cell carcinoma of the penis

<table>
<thead>
<tr>
<th>Author and Design</th>
<th>Regimen</th>
<th>n</th>
<th>Overall survival median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pizzocaro et al.</td>
<td>VBM</td>
<td>25</td>
<td>82% at 5 years</td>
</tr>
<tr>
<td></td>
<td>Vincristine 1 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bleomycin 15 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>methotrexate 30 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weekly × 12 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pizzocaro and Piva</td>
<td>VBM</td>
<td>12</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Vincristine 1 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bleomycin 15 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>methotrexate 30 mg/m²</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weekly × 12 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Box 8. Adjuvant chemotherapy**

**Recommendations**

Patients with N1 disease do not require adjuvant chemotherapy (Grade C).

Adjuvant chemotherapy can be considered in individuals with poor prognostic features including N2-3, lymph node 4 cm or more, extranodal extension) following radical lymph node dissection. Although evidence is sparse, there is potential benefit to considering chemotherapy given the poor outcomes associated with surgery alone in this population. Regimen should be cisplatin based, may contain a taxane and bleomycin should be avoided. Little data is available to guide dose and cycles and we suggest extrapolation of neoadjuvant regimen (Grade C).

**Examples of acceptable adjuvant chemotherapy regimen**

- **TIP:** paclitaxel 175 mg/m² on day 1, ifosfamide 1200 mg/m² on d1 to 3 and cisplatinum 25 mg/m² on day 1 every 3 weeks for 4 cycles
- **Cis-5FU:** cisplatinum 100 mg/m² on day 1, 5FU 1000 mg/m²/day by continuous infusion on day 1-5 every 3 to 4 weeks for 2 cycles
treatment related morbidity and mortality. Treatment with cisplatin-5-FU was notably less toxic and further improved outcomes in patients with pN2-3 disease or extranodal extension. There is also increasing interest in the incorporation of taxanes into the adjuvant regimens and further study in this area is needed.87

There is a paucity of data to guide recommendations for adjuvant chemotherapy in penile cancer (Box 8). We agree with the NCCN guidelines which suggest, on the basis of extrapolation of neoadjuvant data, the use of paclitaxel/ifosphamide/cisplatin for 4 cycles (Table 4).

Unresectable and metastatic disease

Chemotherapy has a role in the management of penile cancer for patients with advanced disease (T4), lymph node metastases, unresectable disease and in the palliation of distant disease. Most of the data evaluating chemotherapy for penile cancer have been generated in the neoadjuvant setting in attempt to downstage unresectable, bulky regional disease (stage III and IV).

Bulky unresectable disease occurs in up to 13.4% of cases. Leijte and colleagues evaluated 5 separate regimens, including bleomycin-methotrexate-cisplatin (BMP) and cisplatin-5-FU (adopted from squamous cell carcinomas of the head and neck).57 Response rates were 33% to 63%; however, bleomycin-containing regimens were associated with increased toxicity and a high rate of treatment-related deaths. Importantly, the authors found that patients achieving objective response to chemotherapy benefitted the most from surgery with a chance for cure. More recently, the activity of taxanes with a cisplatin-containing regimen has been evaluated with promising results. The addition of a taxane to cisplatin-5-FU (adopted from squamous cell carcinomas of the anus and vulva, penis) has been evaluated further by Pagliaro and colleagues.83 It is the largest trial of regionally advanced patients (stage N2 or N3) treated with neoadjuvant chemotherapy, including a total of 30 patients. TIP resulted in a 10% pathologic complete response (pCR) rate and an objective response rate of 50%. This represents a significant improvement over historic controls and suggests a possibility for cure in individuals initially deemed unresectable (Level of evidence 2b). TIP was also less toxic than older regimens, with no treatment-related deaths and the most severe toxicity being febrile neutropenia. Survival advantage correlated with treatment response and absence of extranodal extension or skin involvement. Caveats are the exclusion of patients with visceral metastases, the difficulty in evaluating overall survival data in a nonrandomized phase II study, and, despite being the largest to date, is a study with a small study sample size. In addition, in the setting of bulky or inoperable lymph nodes, multimodality therapy with chemoradiation is widespread practice at large tertiary centres. The preferred regimen for radiosensitizing includes cisplatin alone or in combination with 5-FU or mitomycin C in combination with 5-FU or capecitabine.79 This practice is based on data extrapolated from squamous cell cancers of the anus and vulva, pending a confirming trial specific to squamous penile cancer.

Metastatic disease is associated with a survival of 2 to 12 months. Penile cancer progresses from the inguinal and pelvic lymph nodes to hematogenous spread. The incidence of distant disease at the time of diagnosis is between 1.9% and 7.0%.84 The disease often spreads to the lung, bone, and soft tissue. Chemotherapy can be considered in these patients for potential palliative benefits. Combination chemotherapy using cisplatin-gemcitabine and cisplatin-irinotecan88 has demonstrated encouraging activity and tolerability in patients with metastatic disease. Similar efficacy was observed with bleomycin-containing regimen, but treatment-related mortality was higher. A Southwest Oncology Group study of cisplatin-methotrexate-bleomycin demonstrated a 32.5% response rate (Level of evidence 2b).89 The European Organization for Research and Treatment of Cancer (EORTC) study evaluating cisplatin-irinotecan reported a 31% response rate, although in a heterogenous population that included locally advanced disease (Level of evidence 2b).90 In their recent review of treatment for unresectable penile cancer, Pettaway and colleagues recommended that a cis-

<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Regimen</th>
<th>n</th>
<th>RR %</th>
<th>PFS median</th>
<th>OS median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Di Lorenzo et al.92</td>
<td>First-line retrospective</td>
<td>Cisplatinum 75 mg/m² on day 1 5-fluourouracil 900 mg/m² x 4 days Every 21 days x 4 cycles</td>
<td>25</td>
<td>8 (32)</td>
<td>5 months</td>
<td>8 months</td>
</tr>
<tr>
<td>Di Lorenzo et al.92</td>
<td>Second-line phase II</td>
<td>Paclitaxel 175 mg/m² every 3 weeks</td>
<td>25</td>
<td>5 (20)</td>
<td>2.7 months</td>
<td>5.7 months</td>
</tr>
<tr>
<td>Gagliano et al.105</td>
<td>First-line phase II</td>
<td>Cisplatin 50 mg/m² on day 1 and day 8 Every 21 days</td>
<td>26</td>
<td>4 (15.4)</td>
<td>NR</td>
<td>4.7 months</td>
</tr>
<tr>
<td>Haas et al.88</td>
<td>First-line phase II</td>
<td>Bleomycin 10 mg/m² day 2-6 Methotrexate 200 mg/m² day 1 and 15 Cisplatinum 20 mg/m² day 2-6</td>
<td>40</td>
<td>13 (32.5)</td>
<td>NR</td>
<td>7 months</td>
</tr>
</tbody>
</table>

RR: response rate; PFS: progression-free survival; OS: overall survival.
platin-containing regimen be considered in stage 4 penile cancer and the use of bleomycin-containing regimen was discouraged. The addition of a taxane may be reasonable given the observed objective response rates when used in the neoadjuvant setting for bulky unresectable disease (Box 9).

Limited data are available to evaluate the activity of second-line chemotherapy in pre-treated patient populations. A recent phase II trial of single agent paclitaxel for pre-treated metastatic penile carcinoma showed a response rate of 20% (Level of evidence 2b).

**Chemotherapy for locally recurrent disease**

Local recurrence is more common after penile preservation than after amputation. However, local control can be subsequently achieved in 94% of cases with no significant association between local recurrence and either nodal metastasis or cancer-specific survival (Level of evidence 2b). In particular, surgical salvage after penile preserving treatment with brachytherapy is highly successful, such that local failures do not cause any decrease in cause-specific survival between 5 and 10 years. Local recurrences, however, can occur very late, even up to 10 years after treatment; for this reason, prolonged follow-up is essential. The same phenomenon is reported after penile-preserving laser ablation of superficial disease.

**Box 9. Chemotherapy for metastatic disease**

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic disease should be treated with cisplatin containing regimens. Bleomycin containing regimens should be avoided (Grade C).</td>
</tr>
</tbody>
</table>

In the case of nodal recurrence, neoadjuvant chemotherapy should be considered (Level of evidence 2b). Recent data, however, suggest that response to salvage treatment in patients previously treated with TIP was low (Box 10).

**Biomarkers**

There are no validated markers in penile cancer. p53, Ki67 and E-cadherin have been correlated to lymph node metastasis, but have no role in clinical decision-making. Although the disease is rare, knowledge in part may be garnered by extrapolation from the squamous cell carcinoma experience of other tumour sites, such as head and neck and anal carcinoma in which estimated glomerular filtration rate (EGFR) status and use of anti-EGFR therapies have improved outcomes and predicted response to radiotherapy. A recent retrospective study of erlotinib alone, cetuximab, or cetuximab in combination with cisplatin had an overall survival of 2.8 to 48 months, with a median time to disease progression between 0.37 and more than >37 months. Recent data support the potential for anti-EGFR therapy in penile cancer. Neoadjuvant chemotherapy in combination with EGFR inhibitors followed by consolidative surgical resection is of significant clinical interest; we await results of planned phase II prospective trials.

**Psychosocial considerations**

Residual penile shaft lengths measuring 4 cm or more may preserve erectile and ejaculatory function, but still result in significant reduction of sexual frequency and satisfaction. Although amputation can increase cure rates, the therapeutic benefits must be weighed against the psychosocial morbidity. In a systematic review of quality of life in patients affected by penile cancer, 40% of patients experienced negative effects on well-being; psychiatric symptoms were identified in 50% of patients. There are no standardized intervention tools to date. Knowledge and awareness of the potential impact on psychosocial well-being and the opportunity to intervene may improve quality of life in patients affected by penile cancer.
Post-treatment surveillance

The primary goal of follow-up is to detect local and/or regional recurrences that are potentially curable (Table 6). The goals of treatment in the case of distant metastases are palliative. Surveillance scheduling should be based on the initial treatment. One large series showed that 92.2% of all recurrences occurred within the first 5 years, but may occur more than a decade later. Early detection of recurrence is particularly important with the increasing use of penile-sparing approaches. Regular surveillance also allows us to assess any treatment-related complications and to evaluate our ongoing treatment policy. Patient self-examination as an alternative to examination by a physician may be appropriate for reliable patients. In cases where care is shared with a general practitioner or other healthcare provider, a care plan noting frequency of follow-up, signs/symptoms of concern and reason for re-referral with specific information should be provided. All follow-up should be to a minimum of 5 years, and should be continued indefinitely after penile-sparing approaches.

Summary

Penile cancer is an uncommon, but potentially curable, disease. Most published studies are small, single institution case series and a limited number of non-randomized clinical trials. The rarity of the disease has been prohibitive to large cooperative randomized controlled trials and the available trials and series are too heterogeneous to be combined in a meta-analysis.

Management should occur at an experienced centre. Primary prevention includes avoiding HIV and HPV risk factors, smoking cessation, patient awareness and self-examination. Accurate staging is paramount. PET scans should be considered to improve staging workup. Penile-sparing approaches, including penile-sparing surgery, brachytherapy, or radiotherapy should be considered where possible. The management of the lymph nodes is important and controversial. Goals include maximizing the chance for cure, while minimizing unnecessary lymphadenectomy-associated morbidity. Important concepts include: (i) the use of neoadjuvant chemoradiotherapy in individuals with fixed or relapsed lymph nodes to improve resectability and outcome; (ii) the use of taxane- and cisplatin-containing chemotherapeutic regimen with TIP as an emerging preferred regimen; (iii) the use of chemotherapy in patients with pN2 or pN3 disease following lymph node dissection; and (iv) the similarities between penile cancers and squamous cancers of the head and neck may allow further exploration of EGFR targeted therapies. Patients who are unresponsive to neoadjuvant chemoradiotherapy may undergo palliative surgery. The psychosocial impact of penile cancer should not be forgotten; patients may benefit from psychosocial support.

Future directions include identification of predictors of response to chemotherapy, including HPV status, as seen in head and neck cancers. Ongoing efforts towards accurate prediction of nodal involvement in patients with clinically negative nodes allow for better selection of those patients warranting early surgical resection, while sparing patients at lower risk of nodal involvement the morbidity associated with nodal dissection. The extension of TIP into the adjuvant setting may also be beneficial. In addition, chemotherapy use earlier in disease management may improve penile-preserving strategies and long-term outcomes.

Experience in the field is growing and increasing published reports are becoming available. Collaborative multi-institutional studies are encouraged. The generation of a Canadian registry may allow for increased sample size evaluation and impact analysis of our proposed nationwide guidelines on improving care of patients affected by penile cancer.

Competing interests: Dr. Richter, Dr. Sridhar, Dr. Zalewski, Dr. Crook, Dr. Moretto, Dr. Vennor, Dr. Esen, Dr. Joshua, Dr. Heng, Dr. Soulieres and Dr. Blais all declare no competing financial or personal interests. Dr. Ruether has been a speaker and an Advisory Board consultant for Pfizer, Novartis, Bayer Johnson & Johnson and Astellas and has received honoraria for these roles. He has also be a site principal investigator in clinical trials for Novartis, Pfizer, Astellas, Johnson & Johnson and the Cooperative Group. Dr. Wood has been a member of the Advisory Board for Pfizer, Astellas and Janssen, with no personal financial compensation. She has also participated in clinical trials for GlaxoSmithKline, BMS, Astrellas and Novartis, but has not received personal financial compensation. Dr. Gingerich has participated in an Advisory Board for Amgen. He is also participating in a clinical trial for Oncogenex and Janssens Biotech. Dr. Emmenegger has been a member of the scientific Advisory Board for Amgen, Astellas, Bayer, Janssen, Novartis and Sanofi; he has received honoraria for these roles. He is also a local principal investigator of trials with Oncogenex, Astellas and Teva. Dr. Mukherjee has received a travel grant from Amgen, has received honoraria for his participation in Advisory Boards for Janssen, Astellas, Sanofi and Pfizer. Dr. Heng has also be a local principal investigator for a clinical trial for Astellas, Janssens and Oncogenex. Dr. Czyzykowski is a local investigator for multiple companies, yet has not received direct financial or other renumeration. Dr. Rendon has received honoraria from Amgen, Astellas, Ferring and Janssen for participation in Advisory Boards and their Speaker’s bureau. Dr. Flemcher is a member of the Advisory Board for Amgen, Janssen, Astellas, and Eli Lilly and has received honoraria for his roles. He has also participated in clinical trials for Amgen, Janssen, Medivation, the Ontario Institute for Cancer Research, and Prostate Cancer Canada. Dr. Canil has participated in Advisory Boards for Janssen, Pfizer, Astellas and Amgen. She has received speaking fees for Jansseen and Astellas and travel grants from Novartis and Janssen. She has been an investigator in clinical trials for Pfizer, Janssen, Astellas and Sanofi Oncology.

This paper has been peer-reviewed.

References
